Gene Therapy for Cholestasis: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Catherine Yang and Version 1 by Javier Martínez-García.

Cholestatic diseases can be caused by the dysfunction of transporters involved in hepatobiliary circulation. Although pharmacological treatments constitute the current standard of care for these diseases, none are curative, with liver transplantation being the only long-term solution for severe cholestasis, albeit with many disadvantages. Liver-directed gene therapy has shown promising results in clinical trials for genetic diseases, and it could constitute a potential new therapeutic approach for cholestatic diseases. Gene therapy has emerged as a promising approach to achieve safe, stable, and efficient long-term correction for a wide range of genetic diseases, including monogenic liver disorders, for which liver transplantation remains the only cure, as well as acquired liver diseases.

  • cholestatic diseases
  • gene therapy
  • AAV
  • PFIC

1. Gene Therapy for Acquired Cholestasis

Since no definitive treatment has yet been developed for some acquired hepatic cholestasis, such as PBC and PSC, there is a great need to identify novel therapeutic alternatives that can reduce fibrogenesis and potentially prevent the development of chronic liver injury, making genetic-based treatments an attractive strategy to achieve sustained long-term therapeutic effects.
To generate animal models of acquired cholestatic disorders, interventions including bile duct ligation (BDL) and the induction of cholestasis by drugs, such as estrogens and carbon tetrachloride (CCL4), have been utilized [92][1]. The development of cholestasis involves several processes including: cellular apoptosis, production of proinflammatory cytokines, and fibrogenesis that ultimately leads to biliary impairment [93][2].
Gene therapy approaches for acquired cholestasis have been addressed to mitigate liver damage by reducing apoptosis and fibrosis and improving bile formation (Figure 31). Biomedicines 10 01238 g003 550
Figure 31. Gene therapy approaches for acquired cholestatic diseases. Different gene therapy strategies have resulted in an alleviation of liver disorders according to their anti-apoptotic, anti-inflammatory, and anti-fibrotic properties, respectively. Adv, adenoviral vector; AAV8, adeno-associated vector with serotype 8; ACE2, angiotensin-converting enzyme; AQP-1, aquaporin; Cthrc-1, collagen triple helix repeat containing-1; HNF4a, hepatocyte nuclear factor 4 alpha; IGF, insulin-like growth factor; SOD, superoxide dismutase; uPA, urokinase-plasminogen activator. This figure was created using BioRender.com.

1.1. Apoptosis Attenuation

One of the main targets for gene therapy of acquired liver disorders is the reduction of hepatocyte apoptosis. Hydrodynamic-based gene delivery to the liver of an insulin-like growth factor 1 (IGF-1)-expressing plasmid has demonstrated attenuation of hepatocellular apoptosis and liver injury in rats with BDL. IGF-1 promotes amelioration of cholestatic disease through activation of the phosphatidylinositol-3-kinase pathway, the inhibition of glycogen synthase kinase-3 beta, and the blockade of caspase-9 cleavage. Additionally, inactivation of hepatic stellate cells has been observed, which may explain the notable improvement in the degree of liver fibrosis [94][3].

1.2. Reduction of Mitochondrial Oxidative Stress

Reducing oxidative stress has been shown to be a therapeutic target for acquired liver cholestasis. For example, Adv-mediated mitochondrial superoxide dismutase (SOD) gene delivery leads to a reduction in liver injury by avoiding the formation of oxygen free radicals derived from the accumulation of hydrophobic BAs and preventing the release of proinflammatory cytokines, such as TNFα and TGF-β, in mice with BDL [95][4]. Similarly, administration of Adv vectors expressing an inhibitor gene of proinflammatory cytokine signaling like collagen triple helix repeat containing-1 (Cthrc-1) has shown a reduction of liver fibrosis in mice subjected to BDL and drug-mediated cholestasis through the inhibition of TGF-β signaling caused by the accelerating degradation of phospho-Smad3 [96][5].

1.3. Anti-Fibrotic Therapies

Anti-fibrotic therapies for cholestatic disorders via reducing pro-inflammatory factors tend to promote collagen degradation and thus reduce the degree of liver fibrosis. Adv vectors expressing the urokinase-plasminogen activator (uPA) gene resulted in a slight reduction of liver fibrosis, leading to a partial improvement of liver histology in rats with BDL associated with the activation of metalloproteinases that trigger collagen degradation [97,98][6][7]. Additionally, AAV vectors that allow hepatic expression of angiotensin-converting enzyme (ACE2) provided a sustained anti-fibrotic effect in different animal models of BDL and drug-induced cholestasis [99][8]. A different strategy to fight fibrosis is based on the gene delivery of human hepatocyte nuclear factor 4 alpha (HNF4A) via AAV vectors or mRNA containing LNP. This type of gene therapy was able to decrease the expression of genes involved in profibrogenic activity and revert fibrosis in several mouse models with induced or genetic cholestasis [100][9].

1.4. Amelioration of Bile Flow

Finally, Adv-mediated hepatic delivery of aquaporin-1 (AQP1) has shown an improvement in the bile flow of estrogen-induced cholestatic rats [101][10]. In fact, this approach resulted in a marked reduction of serum ALP, as well as serum and biliary concentrations of bile salts. Moreover, AQP1 gene transfer increased biliary output as mediated by a significant increase in BSEP transport activity [102][11].
Thus, gene therapy approaches may offer a new avenue for the development of novel treatments for acquired cholestatic disorders.

2. Gene Therapy for Inherited Cholestasis

Gene therapy for the treatment of inherited hepatic diseases has garnered a great deal of attention after demonstrating that AAV vectors expressing human coagulation factors IX and VIII in the livers of patients with hemophilia B and A, respectively, resulted in a sustained therapeutic effect for more than three years [103][12]. In fact, a large number of gene therapy products have demonstrated promising therapeutic effects in clinically relevant animal models, leading to clinical trials for inherited liver disorders, such as phenylketonuria, familial hypercholesterolemia, ornithine transcarbamylase deficiency, acute intermittent porphyria, methylmalonic acidemia, and Wilson’s disease, among others [88][13].

2.1. Gene Therapy of Genetic Disorders with Associated Cholestasis

Preclinical studies have shown promising results in animal models of Cerebrotendinous xanthomatosis (CTX) and Crigler-Najjar syndrome type 1. In the first case, the administration of an AAV8 vector expressing CYP27A was able to restore BA metabolism and normalize the concentration of most BAs in plasma in a mouse model of CTX [104][14]. Interestingly, this therapeutic effect was achieved with only 20% of transduced hepatocytes, which could greatly facilitate the clinical translation of this approach. Secondly, treatment of Crigler–Najjar syndrome type 1 with an AAV8 vector expressing UDP-glucuronosyltransferase family 1-member A1 (UGT1A) showed normalization of total serum bilirubin levels in two animal models of the disease, Gunn rats and Ugt1a1-/- mice [105][15]. In this last model, a therapeutic effect was also demonstrated in newborn mice, although high doses of vector were required to maintain the effect [106][16]. These preclinical results led to a phase I/II clinical trial sponsored by Genethon (Évry, France), which is currently ongoing (NCT03466463).
The results observed in preclinical studies of Crigler–Najjar syndrome showed that one of the main limitations for gene therapy of genetic cholestatic diseases could be related to the loss of viral genomes associated with hepatocyte proliferation occurring in young patients [107][17].

2.2. Gene Therapy for PFIC Diseases

Gene therapy approaches for PFIC can be based on gene supplementation or gene editing strategies to modify and repair the affected genes. The implementation of gene therapy for the different types of PFIC has some limitations. Firstly, in some types of PFIC in order to achieve stable and long-term therapeutic efficacy, it could be necessary to transduce most of the hepatocytes, which may require the use of high doses of the viral vector with the concomitant safety concerns [107,108][17][18]. Secondly, some types of PFIC have extrahepatic clinical manifestations hampering the liver-targeted treatment [109][19]. Finally, PFIC diseases requiring therapy are generally diagnosed in pediatric patients, and gene therapy based on non-integrative vectors, such as AAV, may be inefficient due to the loss of viral genomes associated with hepatocyte proliferation in a growing liver [107][17]. The decision to undergo gene therapy for PFIC, as well as the outcome of the therapy, will likely be influenced by the type of mutations present in the affected gene. For example, patients with missense mutations leading to decreased protein activity will probably respond better than those with a complete deficiency.
Although the loss of viral genomes could be a problem for most inherited cholestasis, ABCB4 deficiency, which causes PFIC3, has certain advantages over other PFIC types for liver gene therapy. For example, previous results using hepatocyte transplantation in a mouse model of PFIC3 showed that engraftment of 12% of healthy hepatocytes was enough to achieve therapeutic efficacy [110][20]. This evidence led to four preclinical studies examining the feasibility of gene therapy for PFIC3 in three different Abcb4-/- mouse models with a range of phenotypes depending on the mouse strain [111][21].

Gene Therapy for PFIC3 Based on ABCB4 Supplementation

The first study tested gene therapy in C57BL/6 Abcb4-/- mice that were challenged with a BA-enriched diet to increase liver toxicity due to their mild phenotype. Treatment with an AAV8 vector expressing ABCB4 demonstrated long-term efficacy by preventing the increase of serum transaminases and the loss of biliary PC levels after BA challenge [112][22]. The therapeutic effect was dose dependent, and it was observed that restoration of biliary PC levels above 12–13% (over 4000 µM) of wild-type levels was enough to have a curative effect. This indicates that PFIC3 could be treated even if only a small fraction of hepatocytes were transduced, in this way resembling gene therapy of other diseases like hemophilia B, in which therapeutic effects can be obtained with a small percentage of transduced hepatocytes.
Recently, a preclinical study based on LNP-encapsulated mRNA therapy was able to transiently reverse the disease phenotype in BALB/c Abcb4-/- mice [114][23]. BALB/c Abcb4-/- show similar levels of serum biomarkers as the FVB Abcb4-/- mice, but with a faster progression of liver fibrosis, leading to early development of primary liver cancers as well as an earlier onset of other complications, such as portal hypertension [111][21]. Five repeat ABCB4 mRNA-LNP injections were able to restore ABCB4 expression and biliary PC levels (~42% of wild-type levels), as well as improve serum biomarker levels, liver fibrosis, and hepatomegaly [114,115][23][24]. However, these previously described non-integrative vector-based gene therapy strategies may have important limitations, such as loss of transgene expression, either because of loss of viral genomes due to hepatocyte division or because the short half-life of mRNA requires periodic administration to maintain the therapeutic effect. An alternative strategy to solve this hurdle is gene delivery mediated by an integrative vector.
Using this type of approach, Siew et al. tested PFIC3 correction by the use of an integrative hybrid vector based on the expression of a piggyBac transposase and an AAV8 vector containing a piggyBac ABCB4 expression cassette in FVB Abcb4-/- mice. A single dose of the hybrid vector in neonates demonstrated the recovery of biliary PC levels and normalization of serum biomarkers. Additionally, the hybrid AAV-piggyBac treatment prevented biliary cirrhosis and reduced tumorigenesis [116][25]. However, the possibility of this vector integrating into oncogenic sites represents a high risk for clinical application. Results from these preclinical studies have led to orphan drug designation of an AAV vector harboring a codon optimized version of ABCB4 (VTX-803) developed by Vivet Therapeutics (Paris, France), opening a promising pathway for the treatment of patients with this cholestatic disorder (Table 21).
Table 21. Gene therapy approaches for PFIC3.
Gene therapy approaches for PFIC3.
Biomedicines 10 01238 i001
 Aronson et al. [22]Weber et al. [26]Siew et al. [25]Wei et al. [23]
Strain BackgroundC57BL/6 Abcb4-/-FVB Abcb4-/-FVB Abcb4-/-BALB/c Abcb4-/-
PhenotypeMild

(requiring cholate-enriched diet)		Severe

(similar to patients)		Severe

(similar to patients)		More severe
VectorAAV8AAV8Hybrid AAV-piggyBac transposonLNP
Dose5 × 1013 vg/kg1 × 1014 vg/kg~2 × 1014 vg/kg1.0 mg/kg
Age of treatment10-week-old2- or 5-week-oldNewborn4-week-old
OutcomesIncreased biliary PC and cholesterol content. Rescue of serum ALT, ALP and bilirubin levels. Prevention of liver fibrosis.Increased biliary PC. Rescue of serum transaminases, ALP and BA levels. Improvement of the degree of hepatosplenomegaly. Prevention and reversal of liver fibrosis.Increased biliary PC. Decreased hepatomegaly and serum parameters (ALT, ALP, BAs). Reduced liver fibrosis and liver tumor incidence.Increased biliary PC (10–25% WT) and %BW. Decreased hepatomegaly and serum parameters (ALT, ALP, BAs). Normalization of liver fibrosis and portal hypertension.
AdvantagesLong-term correction. No risk of mutagenesis.Granted orphan drug designation. Long-term prevention and correction at early and late stages of PFIC3, respectively. No risk of mutagenesis.Long-term correction. Preventing genome loss by hepatocellular proliferation during liver growth.No risk of mutagenesis. Less immune responses.
DisadvantagesNeed for challenge with BA-enriched dietary supplementation (model). Need to evaluate efficacy in younger mice more representative of the age of patients. Risks of using a high viral dose.Loss of long-term therapeutic effect in half of the females treated with a single dose. Need to address the immune response based on anti-AAV neutralizing antibody for repeated administrations of the vector. Risks of using a high viral dose.Risk of mutagenesis. Transposase overexpression

Lack of serotype that efficiently transduces human hepatocytes.		Less durable expression. Requires repeated parenteral dosing.
 Aronson et al. [112]Weber et al. [113]Siew et al. [116]Wei et al. [114]
Strain BackgroundC57BL/6 Abcb4-/-FVB Abcb4-/-FVB Abcb4-/-BALB/c Abcb4-/-
PhenotypeMild

(requiring cholate-enriched diet)		Severe

(similar to patients)		Severe

(similar to patients)		More severe
VectorAAV8AAV8Hybrid AAV-piggyBac transposonLNP
Dose5 × 1013 vg/kg1 × 1014 vg/kg~2 × 1014 vg/kg1.0 mg/kg
Age of treatment10-week-old2- or 5-week-oldNewborn4-week-old
OutcomesIncreased biliary PC and cholesterol content. Rescue of serum ALT, ALP and bilirubin levels. Prevention of liver fibrosis.Increased biliary PC. Rescue of serum transaminases, ALP and BA levels. Improvement of the degree of hepatosplenomegaly. Prevention and reversal of liver fibrosis.Increased biliary PC. Decreased hepatomegaly and serum parameters (ALT, ALP, BAs). Reduced liver fibrosis and liver tumor incidence.Increased biliary PC (10–25% WT) and %BW. Decreased hepatomegaly and serum parameters (ALT, ALP, BAs). Normalization of liver fibrosis and portal hypertension.
AdvantagesLong-term correction. No risk of mutagenesis.Granted orphan drug designation. Long-term prevention and correction at early and late stages of PFIC3, respectively. No risk of mutagenesis.Long-term correction. Preventing genome loss by hepatocellular proliferation during liver growth.No risk of mutagenesis. Less immune responses.
DisadvantagesNeed for challenge with BA-enriched dietary supplementation (model). Need to evaluate efficacy in younger mice more representative of the age of patients. Risks of using a high viral dose.Loss of long-term therapeutic effect in half of the females treated with a single dose. Need to address the immune response based on anti-AAV neutralizing antibody for repeated administrations of the vector. Risks of using a high viral dose.Risk of mutagenesis. Transposase overexpression

Lack of serotype that efficiently transduces human hepatocytes.		Less durable expression. Requires repeated parenteral dosing.
AAT, alpha-1 antitrypsin; AAV, adeno-associated vector; ALP, alkaline phosphatase; ALT, alanine aminotransferase; BW, body weight; LNP, lipid nanoparticles; LP1, liver-specific transcriptional control unit; PC, phosphatidylcholine; TRsh, short piggyBac terminal repeats; VG, viral genomes; WT, wild-type.

Gene Therapy for PFIC3 Targeting Mechanisms of Disease

Although gene supplementation or correction of the affected gene is the most straightforward gene therapy strategy for PFIC3, several studies have shown that it is also possible to treat this disease by altering the expression of other genes that are involved in this pathology. One example is the delivery of vectors that express genes that contribute to the attenuation of liver fibrosis, such as ACE2 and HNF4A, as described in Section 3.1.3. In this sense, an AAV8 vector expressing ACE2 was able to reduce liver fibrosis in early- and late-stage FVB Abcb4-/- mice [117][27]. Moreover, hepatocyte-targeted administration of HNF4A mRNA encapsulated with a biodegradable lipid restored the metabolic activity of hepatocytes in FVB Abcb4-/- mice, leading to a robust inhibition of fibrogenesis [100][9].
A novel approach that could be used to treat cholestatic diseases is based on the regulation of BA synthesis and homeostasis. It has recently been described that Limb expression 1-like protein (LIX1L) is increased in the liver of patients with cholestatic diseases and that the normalization of its expression alleviates cholestatic liver injury in different cholestatic mouse models, including FVB Abcb4-/- mice. LIX1L regulates the levels of miR-191-3p, a microRNA that downregulates transcription factor liver receptor homolog-1 (LRH-1), thereby inhibiting Cyp7a1 and Cyp8b1 expression, two enzymes required for BA synthesis. Based on these data, Li et al. [118][28], recently showed that an AAV vector overexpressing miR-191-3p was able to ameliorate cholestasis in FVB Abcb4-/- mice by direct repression of LRH-1 expression, thereby reducing de novo BA synthesis [118][28]. Another potential target for reducing liver fibrosis through gene therapy of cholestatic disorders is the suppression of the neurokinin 1 receptor (NK1R) axis as well as transforming growth factor-β1 (TGF-β1)/miR-31 signaling. In FVB Abcb4-/- mice, knock-out of NK1R has been shown to decrease the levels of miR-31 and of proinflammatory molecules such as TFG-β1, resulting in the reduction of liver inflammation and fibrosis [119][29]. These therapeutic approaches could be very useful for either acquired cholestatic disorders or PFIC.

Gene Therapy for Other Types of PFIC

For other types of PFIC, although gene supplementation using vectors expressing the specific mutated gene is also an option, there are certain barriers that make the development of these treatments more challenging than for PFIC3. For example, patients with PFIC1, PFIC4, PFIC5, and PFIC6 have extrahepatic manifestations that cannot be rescued by liver-targeted gene therapy [109,120][19][30]. In addition, in contrast to gene therapy for PFIC3, where liver toxicity arises in the bile canaliculi and transgene delivery to a fraction of hepatocytes leads to sufficient ABCB4 protein to reverse toxicity, in other types of PFIC where toxicity occurs in hepatocytes, it is likely that correction of a high percentage of these cells will be required to achieve a therapeutic effect [110,121][20][31]. One additional problem to develop gene therapy strategies for some types of PFIC is the lack of suitable animal models that adequately recapitulate the phenotype of patients. Currently, there are no TJP2-deficient animal models available to test the feasibility of gene therapy for PFIC4 [121][31]. Likewise, the existing animal model for PFIC6 is not suitable, because it has a complete knock-out of the MYO5B protein, which is not an appropriate model for this cholestatic disease. For that, it is necessary to develop an animal model with missense mutations of the MYO5B gene that affect the motor domain but do not result in complete deficiency of the protein [122][32]. In the case of PFIC2, there are several animal models that show a varying degree of pathology depending on the genetic background. Abcb11-/- mice in a C57BL/6 background represent the closest model to the patient disease phenotype, showing a drastic decrease in bile salt content in the bile that leads to increased levels of serum transaminases, liver fibrosis, and hepatomegaly, with these changes being more severe in females than in males [123][33]. However, unlike PFIC2 patients, these mice only show a mild elevation of serum bile salts, which is one of the main biomarkers of the disease.
Finally, the loss of transgene expression by hepatocyte cell division is a drawback for the use of non-integrative vectors, such as AAV, in gene therapy of these inherited cholestatic disorders that need to be treated at very early ages, as only a few hepatocytes will maintain episomal AAV genomes [124][34]. Unlike PFIC3, for which partial gene therapy supplementation or correction of the affected gene is feasible, other types of PFIC may benefit from other gene therapy strategies aimed at reversing liver damage at several levels.

References

  1. Mariotti, V.; Strazzabosco, M.; Fabris, L.; Calvisi, D.F. Animal Models of Biliary Injury and Altered Bile Acid Metabolism. Biochim. Biophys. Acta-Mol. Basis Dis. 2018, 1864, 1254–1261.
  2. Fernández-Ramos, D.; Fernández-Tussy, P.; Lopitz-Otsoa, F.; Gutiérrez-de-Juan, V.; Navasa, N.; Barbier-Torres, L.; Zubiete-Franco, I.; Simón, J.; Fernández, A.F.; Arbelaiz, A.; et al. MiR-873-5p Acts as an Epigenetic Regulator in Early Stages of Liver Fibrosis and Cirrhosis. Cell Death Dis. 2018, 9, 958.
  3. Wang, K.P.-C.; Lee, L.-M.; Lin, T.-J.; Sheen-Chen, S.-M.; Lin, J.-W.; Chiu, W.-T.; Wang, C.-C.; Hung, K.-S. Gene Transfer of IGF1 Attenuates Hepatocellular Apoptosis After Bile Duct Ligation. J. Surg. Res. 2011, 167, 237–244.
  4. Zhong, Z.; Froh, M.; Wheeler, M.; Smutney, O.; Lehmann, T.; Thurman, R. Viral Gene Delivery of Superoxide Dismutase Attenuates Experimental Cholestasis-Induced Liver Fibrosis in the Rat. Gene Ther. 2002, 9, 183–191.
  5. Bian, Z.; Miao, Q.; Zhong, W.; Zhang, H.; Wang, Q.; Peng, Y.; Chen, X.; Guo, C.; Shen, L.; Yang, F.; et al. Treatment of Cholestatic Fibrosis by Altering Gene Expression of Cthrc1: Implications for Autoimmune and Non-Autoimmune Liver Disease. J. Autoimmun. 2015, 63, 76–87.
  6. Miranda-Díaz, A.; Rincón, A.R.; Salgado, S.; Vera-Cruz, J.; Gálvez, J.; Islas, M.C.; Berumen, J.; Aguilar Cordova, E.; Armendáriz-Borunda, J. Improved Effects of Viral Gene Delivery of Human UPA plus Biliodigestive Anastomosis Induce Recovery from Experimental Biliary Cirrhosis. Mol. Ther. 2004, 9, 30–37.
  7. Salgado, S.; Garcia, J.; Vera, J.; Siller, F.; Bueno, M.; Miranda, A.; Segura, A.; Grijalva, G.; Segura, J.; Orozco, H.; et al. Liver Cirrhosis Is Reverted by Urokinase-Type Plasminogen Activator Gene Therapy. Mol. Ther. 2000, 2, 545–551.
  8. Mak, K.Y.; Chin, R.; Cunningham, S.C.; Habib, M.R.; Torresi, J.; Sharland, A.F.; Alexander, I.E.; Angus, P.W.; Herath, C.B. ACE2 Therapy Using Adeno-Associated Viral Vector Inhibits Liver Fibrosis in Mice. Mol. Ther. 2015, 23, 1434–1443.
  9. Yang, T.; Poenisch, M.; Khanal, R.; Hu, Q.; Dai, Z.; Li, R.; Song, G.; Yuan, Q.; Yao, Q.; Shen, X.; et al. Therapeutic HNF4A MRNA Attenuates Liver Fibrosis in a Preclinical Model. J. Hepatol. 2021, 75, 1420–1433.
  10. Marrone, J.; Lehmann, G.L.; Soria, L.R.; Pellegrino, J.M.; Molinas, S.; Marinelli, R.A. Adenoviral Transfer of Human Aquaporin -1 Gene to Rat Liver Improves Bile Flow in Estrogen-Induced Cholestasis. Gene Ther. 2014, 21, 1058–1064.
  11. Marrone, J.; Soria, L.R.; Danielli, M.; Lehmann, G.L.; Larocca, M.C.; Marinelli, R.A. Hepatic Gene Transfer of Human Aquaporin-1 Improves Bile Salt Secretory Failure in Rats with Estrogen-induced Cholestasis. Hepatology 2016, 64, 535–548.
  12. Nathwani, A.C.; Tuddenham, E.G.D.; Rangarajan, S.; Rosales, C.; McIntosh, J.; Linch, D.C.; Chowdary, P.; Riddell, A.; Pie, A.J.; Harrington, C.; et al. Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B. N. Engl. J. Med. 2011, 365, 2357–2365.
  13. Maestro, S.; Weber, N.D.; Zabaleta, N.; Aldabe, R.; Gonzalez-Aseguinolaza, G. Novel Vectors and Approaches for Gene Therapy in Liver Diseases. JHEP Rep. 2021, 3, 100300.
  14. Lumbreras, S.; Ricobaraza, A.; Baila-Rueda, L.; Gonzalez-Aparicio, M.; Mora-Jimenez, L.; Uriarte, I.; Bunuales, M.; Avila, M.A.; Monte, M.J.; Marin, J.J.G.; et al. Gene Supplementation of CYP27A1 in the Liver Restores Bile Acid Metabolism in a Mouse Model of Cerebrotendinous Xanthomatosis. Mol. Ther.-Methods Clin. Dev. 2021, 22, 210–221.
  15. Collaud, F.; Bortolussi, G.; Guianvarc’h, L.; Aronson, S.J.; Bordet, T.; Veron, P.; Charles, S.; Vidal, P.; Sola, M.S.; Rundwasser, S.; et al. Preclinical Development of an AAV8-HUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Mol. Ther.-Methods Clin. Dev. 2019, 12, 157–174.
  16. Ronzitti, G.; Bortolussi, G.; van Dijk, R.; Collaud, F.; Charles, S.; Leborgne, C.; Vidal, P.; Martin, S.; Gjata, B.; Sola, M.S.; et al. A Translationally Optimized AAV-UGT1A1 Vector Drives Safe and Long-Lasting Correction of Crigler-Najjar Syndrome. Mol. Ther.-Methods Clin. Dev. 2016, 3, 16049.
  17. Ginocchio, V.M.; Ferla, R.; Auricchio, A.; Brunetti-Pierri, N. Current Status on Clinical Development of Adeno-Associated Virus-Mediated Liver-Directed Gene Therapy for Inborn Errors of Metabolism. Hum. Gene Ther. 2019, 30, 1204–1210.
  18. Bull, L.N.; Thompson, R.J. Progressive Familial Intrahepatic Cholestasis. Clin. Liver Dis. 2018, 22, 657–669.
  19. Bosma, P.J.; Wits, M.; Oude-Elferink, R.P.J. Gene Therapy for Progressive Familial Intrahepatic Cholestasis: Current Progress and Future Prospects. Int. J. Mol. Sci. 2020, 22, 273.
  20. de Vree, J.M.L.; Ottenhoff, R.; Bosma, P.J.; Smith, A.J.; Aten, J.; Oude Elferink, R.P.J. Correction of Liver Disease by Hepatocyte Transplantation in a Mouse Model of Progressive Familial Intrahepatic Cholestasis. Gastroenterology 2000, 119, 1720–1730.
  21. Ikenaga, N.; Liu, S.B.; Sverdlov, D.Y.; Yoshida, S.; Nasser, I.; Ke, Q.; Kang, P.M.; Popov, Y. A New Mdr2−/− Mouse Model of Sclerosing Cholangitis with Rapid Fibrosis Progression, Early-Onset Portal Hypertension, and Liver Cancer. Am. J. Pathol. 2015, 185, 325–334.
  22. Aronson, S.J.; Bakker, R.S.; Shi, X.; Duijst, S.; Bloemendaal, L.T.; de Waart, D.R.; Verheij, J.; Ronzitti, G.; Elferink, R.P.O.; Beuers, U.; et al. Liver-Directed Gene Therapy Results in Long-Term Correction of Progressive Familial Intrahepatic Cholestasis Type 3 in Mice. J. Hepatol. 2019, 71, 153–162.
  23. Wei, G.; Cao, J.; Huang, P.; An, P.; Badlani, D.; Vaid, K.A.; Zhao, S.; Wang, D.Q.-H.; Zhuo, J.; Yin, L.; et al. Synthetic Human ABCB4 MRNA Therapy Rescues Severe Liver Disease Phenotype in a BALB/c.Abcb4 Mouse Model of PFIC3. J. Hepatol. 2021, 74, 1416–1428.
  24. Weber, N.D.; Martínez-García, J.; González-Aseguinolaza, G. Comment on “Synthetic Human ABCB4 MRNA Therapy Rescues Severe Liver Disease Phenotype in a BALB/c.Abcb4 Mouse Model of PFIC3”. J. Hepatol. 2022, 76, 749–751.
  25. Siew, S.M.; Cunningham, S.C.; Zhu, E.; Tay, S.S.; Venuti, E.; Bolitho, C.; Alexander, I.E. Prevention of Cholestatic Liver Disease and Reduced Tumorigenicity in a Murine Model of PFIC Type 3 Using Hybrid AAV-PiggyBac Gene Therapy. Hepatology 2019, 70, 2047–2061.
  26. Weber, N.D.; Odriozola, L.; Martínez-García, J.; Ferrer, V.; Douar, A.; Bénichou, B.; González-Aseguinolaza, G.; Smerdou, C. Gene Therapy for Progressive Familial Intrahepatic Cholestasis Type 3 in a Clinically Relevant Mouse Model. Nat. Commun. 2019, 10, 5694.
  27. Rajapaksha, I.G.; Angus, P.W.; Herath, C.B. Current Therapies and Novel Approaches for Biliary Diseases. World J. Gastrointest. Pathophysiol. 2019, 10, 1–10.
  28. Li, J.; Zhu, X.; Zhang, M.; Zhang, Y.; Ye, S.; Leng, Y.; Yang, T.; Kong, L.; Zhang, H. Limb Expression 1-like (LIX1L) Protein Promotes Cholestatic Liver Injury by Regulating Bile Acid Metabolism. J. Hepatol. 2021, 75, 400–413.
  29. Ceci, L.; Francis, H.; Zhou, T.; Giang, T.; Yang, Z.; Meng, F.; Wu, N.; Kennedy, L.; Kyritsi, K.; Meadows, V.; et al. Knockout of the Tachykinin Receptor 1 in the Mdr2−/− (Abcb4−/−) Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis. Am. J. Pathol. 2020, 190, 2251–2266.
  30. Giang, S.; Gordon, R.L.; Haas, K.B. A Diagnostic Quagmire: PFIC5 Presenting as a Rare Cause of Neonatal Cholestasis. ACG Case Rep. J. 2021, 8, e00558.
  31. Sambrotta, M.; Strautnieks, S.; Papouli, E.; Rushton, P.; Clark, B.E.; Parry, D.A.; Logan, C.V.; Newbury, L.J.; Kamath, B.M.; Ling, S.; et al. Mutations in TJP2 Cause Progressive Cholestatic Liver Disease. Nat. Genet. 2014, 46, 326–328.
  32. Overeem, A.W.; Li, Q.; Qiu, Y.; Cartón-García, F.; Leng, C.; Klappe, K.; Dronkers, J.; Hsiao, N.; Wang, J.; Arango, D.; et al. A Molecular Mechanism Underlying Genotype-Specific Intrahepatic Cholestasis Resulting From MYO5B Mutations. Hepatology 2020, 72, 213–229.
  33. Zhang, Y.; Li, F.; Patterson, A.D.; Wang, Y.; Krausz, K.W.; Neale, G.; Thomas, S.; Nachagari, D.; Vogel, P.; Vore, M.; et al. Abcb11 Deficiency Induces Cholestasis Coupled to Impaired β-Fatty Acid Oxidation in Mice. J. Biol. Chem. 2012, 287, 24784–24794.
  34. Hu, C.; Busuttil, R.W.; Lipshutz, G.S. RH10 Provides Superior Transgene Expression in Mice When Compared with Natural AAV Serotypes for Neonatal Gene Therapy. J. Gene Med. 2010, 12, 766–778.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback